Table 2 Contingency table of SIAH2 expression in invasive breast carcinomas of the combined cohort with clinicopathological parameters
Parameter | Negative, N= 169 (45%) | Positive, N= 209 (55%) | Total, N= 378 (100%) | P value |
|---|---|---|---|---|
Grade | Â | Â | Â | <0.0001 |
   Low | 40 (78.4%) | 11 (21.6%) | 51 (100%) |  |
   Intermediate | 77 (60.2%) | 51 (39.8%) | 128 (100%) |  |
   High | 32 (20.4%) | 125 (79.6%) | 157 (100%) |  |
Age, yr | Â | Â | Â | 0.187 |
   <50 | 48 (39.3%) | 74 (60.7%) | 122 (100%) |  |
   >50 | 107 (47.8%) | 117 (52.1%) | 224 (100%) |  |
Tumor size | Â | Â | Â | 0.168 |
   <20 mm | 89 (48.6%) | 94 (51.4%) | 183 (100%) |  |
   >20 mm | 61 (39.9%) | 92 (60.1%) | 153 (100%) |  |
Lymph node status | Â | Â | Â | 0.915 |
   Negative | 83 (45.4%) | 100 (54.6%) | 147 (100%) |  |
   Positive | 64 (43.0%) | 85 (57.0%) | 185 (100%) |  |
ER status | Â | Â | Â | <0.0001 |
   Negative | 21 (20.8%) | 80 (79.2%) | 101 (100%) |  |
   Positive | 129 (54.4%) | 108 (45.6%) | 237 (100%) |  |
PR status | Â | Â | Â | <0.0001 |
   Negative | 39 (28.5%) | 98 (71.5%) | 137 (100%) |  |
   Positive | 111 (55.2%) | 90 (44.8%) | 201 (100%) |  |
HER2 status | Â | Â | Â | 0.003 |
   Negative | 128 (48.3%) | 137 (51.7%) | 265 (100%) |  |
   Positive | 22 (29.7%) | 52 (70.3%) | 74 (100%) |  |
Tumor subtype | Â | Â | Â | <0.0001 |
   Luminal | 114 (57.6%) | 84 (42.4%) | 198 (100%) |  |
   Basal-like | 4 (9.6%) | 37 (90.2%) | 41 (100%) |  |
   Her2 | 22 (29.3%) | 53 (70.7%) | 75 (100%) |  |
   Null | 11 (44%) | 14 (56%) | 25 (100%) |  |
P53 | Â | Â | Â | Â |
   Negative | 108 (57.8%) | 79 (42.2%) | 187 (100%) | <0.001 |
   Positive | 12 (18.2%) | 54 (81.8%) | 66 (100%) |  |